THE ROLE OF PHARMACEUTICALS IN PUBLIC HEALTH
ACCESS TO ESSENTIAL MEDICINES AS A KEY DETERMINANT TO UNIVERSAL HEALTH COVERAGE

September 15, 2016
9 a.m.–5:30 p.m.

#BUSPH40 #BUSPHSymposia

BU School of Public Health
FOUR DECADES FORWARD
CELEBRATING BU SPH’S 40TH ANNIVERSARY
Health Reform in China, Universal Health Coverage, and Access to Medicines

Ye Lu  Ph.D, Professor
School of Public Health, Fudan University
lye@fudan.edu.cn

Dean’s Symposium
The Role of Pharmaceuticals in Public Health
Boston University School of Public Health
September 15, 2016
• Universal health coverage even in large country like China can be implemented with strong political will.
5 Reform Pillars in China Since 2009

- Speeding up medical security system
- Establishing national essential medicine system
- Improving grass-roots health service system
- Promoting equalization of public health service
- Piloting public hospital reform
National Essential Medicine System

- Establishing a mechanism for list selection
  - 307 products at primary healthcare level in national EML (2009)
  - 520 products at primary healthcare level in national EML (2012)
  - Supplemented at provincial level Included in reimbursable drug list

- Improving access to essential medicines
  - Bidding purchase and uniform distribution at provincial level
  - “government run health care institutions at grass-roots levels shall sell drugs with zero mark up”
  - Essential medicines will be insured, “with the reimbursing rate much higher than that of non-essential medicines”

- Promoting rational use of essential medicines
  - Introducing clinical guidelines and formulary
China’s recent progress and efforts in achieving UHC

- Government input on health care reform
  - USD124 billion of additional public spending for the 1st three years
    - half (USD62 billion) was allocated to subsidize premiums for people to enroll in insurance schemes
    - a third (USD41.3 billion) was used to strengthening the primary care delivery system
    - The rest to paying the recurrent expenses of basic public health services

- Improvements of some key indicators (2008-2015)
  - The average life expectancy: 73.1 → 76.3
  - Maternal mortality rate: 34.2 → 21.7/100,000
  - Infant mortality rate: 14.9‰ → 8.9‰

- Financial protection
  - Population coverage to 97%
  - Benefit package fully expanded to outpatient, inpatient reimbursement rate to 70%,
  - OOP/THE: 40% → 30%
• It has achieved universal population coverage, however the service coverage and risk protection still have much to be done.
Towards universal coverage

- Reduce cost sharing and fees
- Include other services
- Extend to non-covered

- Financial protection: what do people have to pay out-of-pocket?
- Services: which services are covered?

Population: who is covered?
• Government insufficient reimbursement to hospital (Zero mark up policy) may affect the quality
<table>
<thead>
<tr>
<th>Hospital Type</th>
<th>Average revenue per institute</th>
<th>Average government financial subsidy per institute</th>
<th>Average government subsidy as percentage of total revenue (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital</td>
<td>67.41</td>
<td>5.13</td>
<td>7.61</td>
</tr>
<tr>
<td>Public hospitals</td>
<td>109.5</td>
<td>8.93</td>
<td>8.16</td>
</tr>
<tr>
<td>Tertiary hospitals</td>
<td>553.20</td>
<td>37.72</td>
<td>6.82</td>
</tr>
<tr>
<td>Secondary hospitals</td>
<td>83.63</td>
<td>7.85</td>
<td>9.39</td>
</tr>
<tr>
<td>Primary hospital</td>
<td>10.13</td>
<td>1.47</td>
<td>14.51</td>
</tr>
<tr>
<td>Public general hospitals</td>
<td>205.66</td>
<td>15.28</td>
<td>7.43</td>
</tr>
<tr>
<td>Ministry hospitals</td>
<td>2642.61</td>
<td>165.84</td>
<td>6.28</td>
</tr>
<tr>
<td>Provincial hospitals</td>
<td>979.26</td>
<td>71.81</td>
<td>7.33</td>
</tr>
<tr>
<td>Hospitals of prefecture cities</td>
<td>347.73</td>
<td>25.60</td>
<td>7.36</td>
</tr>
<tr>
<td>Hospitals of county level cities</td>
<td>121.82</td>
<td>8.67</td>
<td>7.12</td>
</tr>
<tr>
<td>County hospitals</td>
<td>84.51</td>
<td>7.16</td>
<td>8.5</td>
</tr>
</tbody>
</table>
• Medicine pricing is critical issues dwell the whole process and the pricing negotiation for innovative medicine base on the pharmaceconomic has to be the way forward for big country
Thank you!
THE ROLE OF PHARMACEUTICALS IN PUBLIC HEALTH
ACCESS TO ESSENTIAL MEDICINES AS A KEY DETERMINANT TO UNIVERSAL HEALTH COVERAGE

September 15, 2016
9 a.m.–5:30 p.m.

#BUSPH40 #BUSPHSymposia

BU School of Public Health
FOUR DECADES FORWARD
CELEBRATING BU SPH’S 40TH ANNIVERSARY